DK168485B1 - Carbostyrilderivater, fremgangsmåde til fremstilling deraf og farmaceutisk præparat indeholdende et sådant carbostyrilderivat - Google Patents

Carbostyrilderivater, fremgangsmåde til fremstilling deraf og farmaceutisk præparat indeholdende et sådant carbostyrilderivat Download PDF

Info

Publication number: DK168485B1
Authority: DK; Denmark
Prior art keywords: carbostyril; formula; group; salt; carbon
Prior art date: 1988-10-31

Application number

DK539789A

Other languages

Danish (da)

English (en)

Other versions

DK539789D0 (da

DK539789A (da

Inventor

Yasuo Oshiro

Seiji Sato

Nobuyuki Kurahashi

Original Assignee

Otsuka Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-10-31

Filing date

1989-10-30

Publication date

1994-04-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17576714&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK168485(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1989-10-30 Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd

1989-10-30 Publication of DK539789D0 publication Critical patent/DK539789D0/da

1990-05-01 Publication of DK539789A publication Critical patent/DK539789A/da

1994-04-05 Application granted granted Critical

1994-04-05 Publication of DK168485B1 publication Critical patent/DK168485B1/da

Links

LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title claims description 60
238000002360 preparation method Methods 0.000 title claims description 17
238000000034 method Methods 0.000 title claims description 13
239000008194 pharmaceutical composition Substances 0.000 title claims description 13
150000001875 compounds Chemical class 0.000 claims description 73
-1 2-methyl-3-nitrophenyl group Chemical group 0.000 claims description 29
150000003839 salts Chemical class 0.000 claims description 28
239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 18
201000000980 schizophrenia Diseases 0.000 claims description 17
125000005843 halogen group Chemical group 0.000 claims description 13
125000001309 chloro group Chemical group Cl* 0.000 claims description 12
229910052801 chlorine Inorganic materials 0.000 claims description 10
CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical group ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 8
NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims description 6
WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid Chemical group OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 6
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 4
238000006467 substitution reaction Methods 0.000 claims description 4
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
POSMARWRXDNPAX-UHFFFAOYSA-N 7-[4-[4-(2-ethoxyphenyl)piperazin-1-yl]butoxy]-1h-quinolin-2-one Chemical compound CCOC1=CC=CC=C1N1CCN(CCCCOC=2C=C3NC(=O)C=CC3=CC=2)CC1 POSMARWRXDNPAX-UHFFFAOYSA-N 0.000 claims 2
LAUHOTTZDXINOP-UHFFFAOYSA-N 7-[4-[4-(2-ethoxyphenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound CCOC1=CC=CC=C1N1CCN(CCCCOC=2C=C3NC(=O)CCC3=CC=2)CC1 LAUHOTTZDXINOP-UHFFFAOYSA-N 0.000 claims 2
GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
HVXIHKMBKZOTLQ-UHFFFAOYSA-N formic acid;1h-quinolin-2-one Chemical compound OC=O.C1=CC=C2NC(=O)C=CC2=C1 HVXIHKMBKZOTLQ-UHFFFAOYSA-N 0.000 claims 2
125000004429 atom Chemical group 0.000 claims 1
125000001246 bromo group Chemical group Br* 0.000 claims 1
150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
229910052736 halogen Inorganic materials 0.000 claims 1
150000002367 halogens Chemical class 0.000 claims 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
238000006243 chemical reaction Methods 0.000 description 32
230000000694 effects Effects 0.000 description 24
239000000243 solution Substances 0.000 description 19
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
150000007514 bases Chemical class 0.000 description 17
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
229940079593 drug Drugs 0.000 description 15
239000003814 drug Substances 0.000 description 14
235000002639 sodium chloride Nutrition 0.000 description 14
239000002904 solvent Substances 0.000 description 13
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
239000007924 injection Substances 0.000 description 12
238000002347 injection Methods 0.000 description 12
238000012360 testing method Methods 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
239000003795 chemical substances by application Substances 0.000 description 10
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
230000003291 dopaminomimetic effect Effects 0.000 description 9
239000000203 mixture Substances 0.000 description 9
239000000843 powder Substances 0.000 description 9
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
239000003826 tablet Substances 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
229920002472 Starch Polymers 0.000 description 8
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
239000008107 starch Substances 0.000 description 8
235000019698 starch Nutrition 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
230000003354 anti-apomorphinic effect Effects 0.000 description 6
230000000903 blocking effect Effects 0.000 description 6
229960005139 epinephrine Drugs 0.000 description 6
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
235000011121 sodium hydroxide Nutrition 0.000 description 6
239000000725 suspension Substances 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
150000001298 alcohols Chemical class 0.000 description 5
125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 5
239000008101 lactose Substances 0.000 description 5
239000000825 pharmaceutical preparation Substances 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
235000011118 potassium hydroxide Nutrition 0.000 description 5
229910000029 sodium carbonate Inorganic materials 0.000 description 5
235000017550 sodium carbonate Nutrition 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
150000004945 aromatic hydrocarbons Chemical class 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
239000013078 crystal Substances 0.000 description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
239000008103 glucose Substances 0.000 description 4
229910000027 potassium carbonate Inorganic materials 0.000 description 4
235000011181 potassium carbonates Nutrition 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
239000008096 xylene Substances 0.000 description 4
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
239000005995 Aluminium silicate Substances 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
235000012211 aluminium silicate Nutrition 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
230000005540 biological transmission Effects 0.000 description 3
229910000019 calcium carbonate Inorganic materials 0.000 description 3
235000010216 calcium carbonate Nutrition 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229940110456 cocoa butter Drugs 0.000 description 3
235000019868 cocoa butter Nutrition 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
230000001665 lethal effect Effects 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000006187 pill Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
239000012312 sodium hydride Substances 0.000 description 3
229910000104 sodium hydride Inorganic materials 0.000 description 3
235000009518 sodium iodide Nutrition 0.000 description 3
239000007858 starting material Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
230000005062 synaptic transmission Effects 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
URHLNHVYMNBPEO-UHFFFAOYSA-N 7-(4-bromobutoxy)-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CC(=O)NC2=CC(OCCCCBr)=CC=C21 URHLNHVYMNBPEO-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
206010001540 Akathisia Diseases 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
208000012661 Dyskinesia Diseases 0.000 description 2
208000014094 Dystonic disease Diseases 0.000 description 2
241001466453 Laminaria Species 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
208000001431 Psychomotor Agitation Diseases 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
239000008272 agar Substances 0.000 description 2
235000010419 agar Nutrition 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
229910001516 alkali metal iodide Inorganic materials 0.000 description 2
150000001340 alkali metals Chemical class 0.000 description 2
230000001387 anti-histamine Effects 0.000 description 2
239000000739 antihistaminic agent Substances 0.000 description 2
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
229960004046 apomorphine Drugs 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
229960003638 dopamine Drugs 0.000 description 2
208000010118 dystonia Diseases 0.000 description 2
239000003480 eluent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000008187 granular material Substances 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
239000011976 maleic acid Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
239000011736 potassium bicarbonate Substances 0.000 description 2
235000015497 potassium bicarbonate Nutrition 0.000 description 2
229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
229940086066 potassium hydrogencarbonate Drugs 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
238000010992 reflux Methods 0.000 description 2
238000010898 silica gel chromatography Methods 0.000 description 2
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
235000010262 sodium metabisulphite Nutrition 0.000 description 2
239000000126 substance Substances 0.000 description 2
IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
CSRBUGKXVBFZKG-UHFFFAOYSA-N 1-(2-chloro-3-methylphenyl)piperazine Chemical compound CC1=CC=CC(N2CCNCC2)=C1Cl CSRBUGKXVBFZKG-UHFFFAOYSA-N 0.000 description 1
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
UDQMXYJSNNCRAS-UHFFFAOYSA-N 2,3-dichlorophenylpiperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1Cl UDQMXYJSNNCRAS-UHFFFAOYSA-N 0.000 description 1
RQRKMXABSUYQBV-UHFFFAOYSA-N 2-chloro-3-methylaniline Chemical compound CC1=CC=CC(N)=C1Cl RQRKMXABSUYQBV-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
LZAYOZUFUAMFLD-UHFFFAOYSA-N 4-(4-chlorophenyl)-4-hydroxypiperidine Chemical compound C=1C=C(Cl)C=CC=1C1(O)CCNCC1 LZAYOZUFUAMFLD-UHFFFAOYSA-N 0.000 description 1
NRCCHQWXUDIGMQ-UHFFFAOYSA-N 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one sulfuric acid Chemical compound OS(O)(=O)=O.ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl NRCCHQWXUDIGMQ-UHFFFAOYSA-N 0.000 description 1
PEQPTQQEFPZVMP-UHFFFAOYSA-N 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1h-quinolin-2-one;hydrochloride Chemical compound Cl.ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl PEQPTQQEFPZVMP-UHFFFAOYSA-N 0.000 description 1
LKLSFDWYIBUGNT-UHFFFAOYSA-N 7-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CC(=O)NC2=CC(O)=CC=C21 LKLSFDWYIBUGNT-UHFFFAOYSA-N 0.000 description 1
206010002942 Apathy Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000009132 Catalepsy Diseases 0.000 description 1
206010012239 Delusion Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
244000165918 Eucalyptus papuana Species 0.000 description 1
DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
208000027089 Parkinsonian disease Diseases 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
241000394605 Viola striata Species 0.000 description 1
206010047853 Waxy flexibility Diseases 0.000 description 1
239000003655 absorption accelerator Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical class OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
229940126543 compound 14 Drugs 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
231100000868 delusion Toxicity 0.000 description 1
238000013461 design Methods 0.000 description 1
239000012973 diazabicyclooctane Substances 0.000 description 1
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
229940043264 dodecyl sulfate Drugs 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
ROAYSRAUMPWBQX-UHFFFAOYSA-N ethanol;sulfuric acid Chemical compound CCO.OS(O)(=O)=O ROAYSRAUMPWBQX-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
108010025899 gelatin film Proteins 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
208000031424 hyperprolactinemia Diseases 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
239000007788 liquid Substances 0.000 description 1
244000144972 livestock Species 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000002304 perfume Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229960003975 potassium Drugs 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
229910000105 potassium hydride Inorganic materials 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000012746 preparative thin layer chromatography Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical compound CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
230000000506 psychotropic effect Effects 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
238000012552 review Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
239000004208 shellac Substances 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
239000004296 sodium metabisulphite Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
229960004940 sulpiride Drugs 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000007306 turnover Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK539789A 1988-10-31 1989-10-30 Carbostyrilderivater, fremgangsmåde til fremstilling deraf og farmaceutisk præparat indeholdende et sådant carbostyrilderivat DK168485B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP27695388		1988-10-31
JP27695388		1988-10-31

Publications (3)

Publication Number	Publication Date
DK539789D0 DK539789D0 (da)	1989-10-30
DK539789A DK539789A (da)	1990-05-01
DK168485B1 true DK168485B1 (da)	1994-04-05

Family

ID=17576714

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK539789A DK168485B1 (da)	1988-10-31	1989-10-30	Carbostyrilderivater, fremgangsmåde til fremstilling deraf og farmaceutisk præparat indeholdende et sådant carbostyrilderivat

Country Status (10)

Country	Link
US (1)	US5006528A (zh)
EP (1)	EP0367141B1 (zh)
KR (1)	KR0138529B1 (zh)
CN (1)	CN1028104C (zh)
DE (2)	DE68925405T2 (zh)
DK (1)	DK168485B1 (zh)
ES (1)	ES2084594T3 (zh)
HK (1)	HK1002706A1 (zh)
MX (1)	MX9202934A (zh)
NL (1)	NL300161I2 (zh)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2311734C (en) *	2000-04-12	2011-03-08	Bristol-Myers Squibb Company	Flash-melt oral dosage formulation
AR032641A1 (es) *	2001-01-29	2003-11-19	Otsuka Pharma Co Ltd	Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en)	2001-01-29	2006-05-30	Otsuka Pharmaceutical Co., Ltd.	5-HT1a receptor subtype agonist
MY129350A (en) *	2001-04-25	2007-03-30	Bristol Myers Squibb Co	Aripiprazole oral solution
PE20030445A1 (es) *	2001-09-25	2003-07-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
AR033485A1 (es) *	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en)	2001-09-25	2014-04-22	Otsuka Pharmaceutical Co., Ltd.	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
RU2259366C2 (ru) *	2001-09-25	2005-08-27	Оцука Фармасьютикал Ко., Лтд.	Арипипразоловое лекарственное средство с низкой гигроскопичностью и способы его получения
TWI324074B (en) *	2001-10-09	2010-05-01	Bristol Myers Squibb Co	Flashmelt oral dosage formulation
SE0200301D0 (sv) *	2002-02-01	2002-02-01	Axon Biochemicals Bv	Thio-carbostyril derivative
SI1542668T1 (sl) *	2002-08-20	2009-08-31	Bristol Myers Squibb Co	Aripiprazol sestavljena formulacija in postopek
GB0220581D0 (en)	2002-09-04	2002-10-09	Novartis Ag	Organic Compound
US20040185110A1 (en) *	2002-11-08	2004-09-23	Ronald Harland	Formulations of low solubility bioactive agents and processes for making the same
AR042806A1 (es) *	2002-12-27	2005-07-06	Otsuka Pharma Co Ltd	Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
NZ540054A (en)	2002-12-27	2007-09-28	Otsuka Pharma Co Ltd	Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
DE60302139T3 (de) *	2003-01-09	2011-02-24	Otsuka Pharmaceutical Co., Ltd.	Verfahren zur herstellung von aripiprazole
US7658998B2 (en) *	2003-01-22	2010-02-09	Alkermes Controlled Therapeutics, Inc.	Method of preparing sustained release microparticles
EP1606262A1 (en) *	2003-03-21	2005-12-21	Hetero Drugs Limited	Novel crystalline forms of aripiprazole
US20060270683A1 (en) *	2003-04-25	2006-11-30	Lohray Braj B	Polymorphs of aripiprazole
CA2428237C (en) *	2003-05-08	2010-07-20	Delmar Chemicals Inc.	Process for the preparation of carbostyril derivatives
AU2004237951A1 (en) *	2003-05-16	2004-11-25	Pfizer Products Inc.	Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
DK1626721T3 (en) *	2003-05-23	2017-01-23	Otsuka Pharma Co Ltd	CARBOSTYRIL DERIVATIVES AND Mood Stabilizers for the Treatment of Mood Disorders
WO2005009990A1 (en) *	2003-07-25	2005-02-03	Hetero Drugs Limited	Aripiprazole crystalline forms
US20050032811A1 (en)	2003-08-06	2005-02-10	Josiah Brown	Methods for administering aripiprazole
US20050031713A1 (en) *	2003-08-06	2005-02-10	Elliot Ehrich	Methods for administering active agents to CYP3A4 sensitive patients
US6987111B2 (en)	2003-08-06	2006-01-17	Alkermes Controlled Therapeutics, Ii	Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032781A1 (en) *	2003-08-06	2005-02-10	Elliot Ehrich	Methods for administering active agents to CYP 2D6 sensitive patients
US7160888B2 (en) *	2003-08-22	2007-01-09	Warner Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
ATE442364T1 (de) *	2003-10-16	2009-09-15	Symed Labs Ltd	Kristalline form von linezolid
SI1675573T2 (sl) *	2003-10-23	2012-08-31	Otsuka Pharma Co Ltd	Sterilna injektibilna aripiprazolna formulacija z nadzorovanim sproĹˇÄŤanjem in postopek
TWI371274B (en)	2003-10-23	2012-09-01	Bristol Myers Squibb Co	Process for making sterile aripiprazole of desired mean particle size
GB0326148D0 (en)	2003-11-10	2003-12-17	Lilly Co Eli	Morpholine derivatives
ATE529409T1 (de)	2003-12-16	2011-11-15	Teva Pharma	Verfahren zur herstellung von kristallinen aripiprazolformen
US7714129B2 (en) *	2003-12-16	2010-05-11	Teva Pharmaceutical Industries Ltd.	Methods of preparing anhydrous aripiprazole form II
CN1304373C (zh) *	2003-12-25	2007-03-14	成都康弘科技实业（集团）有限公司	阿立哌唑的制备方法和中间体
WO2006001846A1 (en) *	2004-02-05	2006-01-05	Teva Pharmaceutical Industries Ltd.	Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril
EP1711466A1 (en) *	2004-02-05	2006-10-18	Teva Pharmaceutical Industries Ltd	Process for preparing aripiprazole
CN100497325C (zh) *	2004-04-21	2009-06-10	齐鲁制药有限公司	哌嗪衍生物及其在制备喹啉酮衍生物中的用途
US7507823B2 (en) *	2004-05-06	2009-03-24	Bristol-Myers Squibb Company	Process of making aripiprazole particles
EP1753460A2 (en) *	2004-05-11	2007-02-21	Pfizer Products Inc.	Combination of atypical antipsychotics and 5-ht1b receptor antagonists
AR049401A1 (es)	2004-06-18	2006-07-26	Novartis Ag	Aza-biciclononanos
WO2006012237A2 (en) *	2004-06-25	2006-02-02	Shanghai Institute Of Pharmaceutical Industry	Aripiprazole crystaline forms and associated methods
TW200616608A (en) *	2004-07-09	2006-06-01	Forest Laboratories	Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
GB0415746D0 (en)	2004-07-14	2004-08-18	Novartis Ag	Organic compounds
US20060024362A1 (en) *	2004-07-29	2006-02-02	Pawan Seth	Composition comprising a benzimidazole and process for its manufacture
US20090198059A1 (en) *	2004-09-13	2009-08-06	Chava Satyanarayana	Process for the preparation of polymorphs, solvates of aripiprazole using aripirazole acid salts
AU2004323810B2 (en) *	2004-10-08	2011-11-17	Suven Life Sciences Limited	Novel intermediates useful for the preparation of aripiprazole and methods for the preparation of the novel intermediates and aripiprazole
DE102005048694A1 (de) *	2004-10-12	2006-05-18	Chemagis Ltd.	Verbesserte Verfahren zur Herstellung von 7-Hydroxy-3,4-dihydro-2(1H)-quinolinon und dessen Verwendung in der Herstellung von Aripiprazol
DE102005048695A1 (de) *	2004-10-12	2006-05-18	Chemagis Ltd.	Verfahren zur Herstellung und Reinigung von Carbostyrilverbindungen wie beispielsweise Aripiprazol und 7-(4-Halobutoxy)-3,4-dihydro-2(1H)-quinolinonen
GB0424564D0 (en) *	2004-11-05	2004-12-08	Novartis Ag	Organic compounds
WO2006053781A1 (en) *	2004-11-18	2006-05-26	Synthon B.V.	Process of making crystalline aripiprazole
WO2006053780A1 (en)	2004-11-18	2006-05-26	Synthon B.V.	Crystalline aripiprazole solvates
CN1303068C (zh) *	2005-01-11	2007-03-07	中国人民解放军第二军医大学	一种阿立哌唑的制备方法
EP1686126A1 (en) *	2005-01-27	2006-08-02	Sandoz AG	Salts of aripiprazole
EP1686117A1 (en) *	2005-01-27	2006-08-02	Sandoz AG	Polymorph and solvates of aripiprazole
WO2006079549A1 (en) *	2005-01-27	2006-08-03	Sandoz Ag	Salts of aripiprazole
CZ300456B6 (cs) *	2005-02-15	2009-05-27	Zentiva, A. S.	Zpusob prípravy vinanu aripiprazolu v krystalické forme
CZ300352B6 (cs) *	2005-02-15	2009-04-29	Zentiva, A. S.	Zpusob prípravy fosforecnanu aripiprazolu
WO2006090272A1 (en) *	2005-02-22	2006-08-31	Warner-Lambert Company Llc	Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia
CA2600542A1 (en) *	2005-03-17	2006-09-21	Synthon B.V.	Pharmaceutical tablets of crystalline type ii aripiprazole
WO2006097343A1 (en) †	2005-03-17	2006-09-21	Synthon B.V.	Process of making crystalline type ii aripiprazole
EA200701856A1 (ru) *	2005-04-01	2008-02-28	Уорнер-Ламберт Компани Ллс	Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
GB0507298D0 (en)	2005-04-11	2005-05-18	Novartis Ag	Organic compounds
TWI320783B (en)	2005-04-14	2010-02-21	Otsuka Pharma Co Ltd	Heterocyclic compound
CZ300351B6 (cs) *	2005-05-26	2009-04-29	Zentiva, A. S.	Zpusob prípravy 7-hydroxy-3,4-dihydrokarbostyrilu
CN100432053C (zh) *	2005-06-07	2008-11-12	上海医药工业研究院	阿立哌唑晶型及其制备方法
HUP0500683A3 (en) *	2005-07-14	2009-03-30	Egis Gyogyszergyar Nyilvanosan	New arylpiprazole salts for producing pharmaceutical composition
TWI329641B (en)	2005-08-31	2010-09-01	Otsuka Pharma Co Ltd	(benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
WO2007035348A2 (en) *	2005-09-15	2007-03-29	Elan Pharma International, Limited	Nanoparticulate aripiprazole formulations
MX2007006368A (es)	2005-09-29	2007-07-11	Teva Pharma	Metodos de preparacion de aripiprazol anhidro forma ii.
CZ299485B6 (cs) *	2005-10-11	2008-08-13	Zentiva, A. S.	Zpusob výroby aripiprazolu
GB0525673D0 (en)	2005-12-16	2006-01-25	Novartis Ag	Organic compounds
GB0525672D0 (en)	2005-12-16	2006-01-25	Novartis Ag	Organic compounds
BRPI0608185A2 (pt) *	2005-12-22	2009-11-17	Teva Pharma	processo para redução do tamanho de partìcula de aripiprazol
US20070149782A1 (en) *	2005-12-23	2007-06-28	Michael Brand	Methods of preparing a crystalline form of 7-(4-chlorobutoxy)-3,4-dihydro-2(1h)-quinolinone and the use thereof in the synthesis of Aripiprazole
US20090054455A1 (en) *	2006-02-03	2009-02-26	Dr. Reddy's Laboratories Ltd.	Aripiprazole co-crystals
EP1988077A4 (en)	2006-02-23	2009-09-02	Shionogi & Co	NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS
US20070213535A1 (en) *	2006-03-07	2007-09-13	Chemagis Ltd.	Process for the manufacture of aripiprazole by using purified carbostyril compounds such as 7-(4-halobutoxy)-3,4-dihydro-2(1H)-quinolinones
US20060223820A1 (en) *	2006-03-21	2006-10-05	Chemagis Ltd.	Crystalline aripiprazole salts and processes for preparation and purification thereof
WO2007113846A1 (en) *	2006-04-03	2007-10-11	Alembic Limited	A process for the preparation of aripiprazole
DE602007001620D1 (de) *	2006-04-10	2009-09-03	Ranbaxy Lab Ltd	Verbesserter Herstellungsprozess für Aripipirazol
US20100021891A1 (en)	2006-06-12	2010-01-28	Bernard Lerer	Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
WO2007148191A2 (en) *	2006-06-20	2007-12-27	Orchid Chemicals & Pharmaceuticals Limited	An improved process for the preparation of aripiprazole
WO2008001188A2 (en) *	2006-06-29	2008-01-03	Cadila Pharmaceuticals Limited	An improved process for the preparation of substantially pure aripiprazole
EP1880714A1 (en) *	2006-07-20	2008-01-23	Helm AG	Amorphous Aripiprazole and Process for the Preparation thereof
US7799790B2 (en) *	2006-07-20	2010-09-21	Helm Ag	Amorphous aripiprazole and process for the preparation thereof
TR200604349A2 (tr)	2006-08-15	2008-03-21	NOBEL İLAÇ SANAYii VE TiCARET A.Ş.	Aripiprazol içeren farmasötik bileşimler
EP2063893A2 (en) *	2006-08-24	2009-06-03	Concert Pharmaceuticals Inc.	3,4-dihydro-2 (1h) - quinolinone and 2 (1h)-quinolinone derivatives
WO2008034628A1 (en) *	2006-09-22	2008-03-27	Krka, Tovarna Zdravil, D.D., Novo Mesto	Aripiprazole hemifumarate and process for its preparation
WO2008059518A2 (en) *	2006-09-28	2008-05-22	Cadila Healthcare Limited	Process for preparing crystalline aripiprazole
US8039621B2 (en) *	2006-10-24	2011-10-18	Cambrex Charles City, Inc.	Process for preparing anhydrous Aripirazole type I
KR101141185B1 (ko) *	2007-01-26	2012-07-12	오쓰까 세이야꾸 가부시키가이샤	치료의 제안된 효능 검출용 마커
EP1972628A1 (en) *	2007-03-21	2008-09-24	Schwarz Pharma Ag	Indolizines and aza-analog derivatives thereof as CNS active compounds
TW200848041A (en)	2007-03-30	2008-12-16	Otsuka Pharma Co Ltd	A medicament for treating schizophrenia comprising cilostazol
NZ582124A (en)	2007-05-21	2012-07-27	Reviva Pharmaceuticals Inc	Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
US20080299216A1 (en) *	2007-06-01	2008-12-04	Protia, Llc	Deuterium-enriched aripiprazole
WO2008146156A2 (en) *	2007-06-01	2008-12-04	Aurobindo Pharma Limited	An improved process for the preparation of aripiprazole
NZ582415A (en) *	2007-07-31	2012-05-25	Otsuka Pharma Co Ltd	Methods for producing aripiprazole suspension and freeze-dried formulation
GB2456183A (en) *	2008-01-04	2009-07-08	Gw Pharma Ltd	Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
DE602008002809D1 (de)	2008-01-23	2010-11-11	Helm Ag	Amorphes Aripiprazol und Verfahren zu seiner Herstellung
CN101538252B (zh) *	2008-03-20	2011-04-20	成都康弘药业集团股份有限公司	阿立哌唑的制备方法及其中间体
US7964605B2 (en) *	2008-05-29	2011-06-21	Sk Holdings Co., Ltd.	Phenyl piperazine compounds, pharmaceutical composition comprising the same, and use thereof
US7985752B2 (en) *	2008-05-29	2011-07-26	Sk Holdings Co., Ltd.	Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof
WO2010079506A2 (en)	2008-06-23	2010-07-15	Torrent Pharmaceuticals Ltd.	Pharmaceutical composition of aripiprazole
EP2321011A1 (en) *	2008-06-25	2011-05-18	Pfizer Inc.	Diaryl compounds and uses thereof
EP2233471A1 (en)	2009-02-06	2010-09-29	Adamed Sp. z o.o.	A salt of 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4.dihydro-2(1h)-quinolinone with 5-sulfosalicylic acid and its preparation process
WO2010106551A2 (en) *	2009-03-09	2010-09-23	Neuland Laboratories Ltd.	A process for the manufacture of pure anhydrous aripiprazole form b
EP2238976B1 (en)	2009-04-03	2012-06-27	Hexal AG	Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
JP5664871B2 (ja)	2009-06-19	2015-02-04	株式会社メドレックス	アリピプラゾールと有機酸を有効成分とする外用剤組成物
US8431576B2 (en)	2009-06-25	2013-04-30	Alkermes Pharma Ireland Limited	Heterocyclic compounds for the treatment of neurological and psychological disorders
JP5732453B2 (ja)	2009-06-25	2015-06-10	アルカーメスファーマアイルランドリミテッド	Ｎｈ酸性化合物のプロドラッグ
WO2011023796A1 (en)	2009-08-31	2011-03-03	Abbott Healthcare Products B.V.	Bifeprunox for treating addiction
KR20160147061A (ko)	2009-09-11	2016-12-21	오츠카 세이야쿠 가부시키가이샤	만성 동통 치료제
WO2011030213A1 (en)	2009-09-14	2011-03-17	Jubilant Organosys Limited	Improved process for the preparation of 7.(4-bromobutoxy) 3,4-dihydrocarbostyril, a precursor of aripiprazole
EP2477609A1 (en)	2009-09-15	2012-07-25	Ratiopharm GmbH	Orally disintegrating pharmaceutical dosage form containing aripiprazole
TR201000948A1 (tr)	2010-02-09	2011-08-22	Sanovel İlaç San.Ve Ti̇c.A.Ş.	Aripiprazol formülasyonları.
JP2013528658A (ja)	2010-06-16	2013-07-11	エンベラニューロセラピューティクス，インコーポレイティド	依存、精神疾患、及び神経変性病の治療のための組成物と方法
US8592427B2 (en)	2010-06-24	2013-11-26	Alkermes Pharma Ireland Limited	Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9156822B2 (en)	2010-07-02	2015-10-13	The University Of North Carolina At Chapel Hill	Functionally selective ligands of dopamine D2 receptors
ES2705726T3 (es)	2010-08-23	2019-03-26	Alkermes Pharma Ireland Ltd	Métodos para tratar el aumento de peso inducido por antipsicóticos
ES2685469T3 (es)	2010-08-24	2018-10-09	Otsuka Pharmaceutical Co., Ltd.	Suspensión y composición de torta que contienen derivado de carboestirilo y aceite de silicona y/o derivado de aceite de silicona
BR112013012062B1 (pt)	2010-11-15	2020-06-02	Agenebio, Inc	Composto derivado da piridazina ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso do composto
AR083884A1 (es)	2010-11-16	2013-03-27	Otsuka Pharma Co Ltd	Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa
HRP20211295T1 (hr)	2011-01-24	2021-11-12	Otsuka Pharmaceutical Co., Ltd.	Medicinski uređaj koji sadrži pripravak za kolače koji sadrži aripiprazol kao aktivni sastojak, te pripravak za kolače koji sadrži aripiprazol kao aktivni sastojak
LT2685979T (lt)	2011-03-18	2016-12-12	Alkermes Pharma Ireland Limited	Injekcinės farmacinės kompozicijos, apimančios vandenyje netirpų antipsichotiką, sorbitano lauratą ir polisorbatą 20
WO2012131451A1 (en)	2011-03-30	2012-10-04	Jubilant Life Sciences Limited	Process for producing aripiprazole in anhydrous type i crystals
KR101340214B1 (ko)	2011-03-31	2013-12-10	주식회사 대웅제약	무수 아리피프라졸 ⅱ형 결정의 제조방법
JO3410B1 (ar)	2011-06-07	2019-10-20	Otsuka Pharma Co Ltd	تركيبة أريبيبرازول مجفف بالتبريد
TW201309651A (zh)	2011-06-29	2013-03-01	Otsuka Pharma Co Ltd	阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
GR1007722B (el)	2011-08-05	2012-10-18	Φαρματεν Αβεε,	Μεθοδος για την παρασκευη της αριπιπραζολης
AU2012351747B2 (en)	2011-12-15	2016-05-12	Alkermes Pharma Ireland Limited	Prodrugs of secondary amine compounds
CN103172563B (zh) *	2011-12-26	2015-03-25	北京京卫燕康药物研究所有限公司	小粒径的晶型i阿立哌唑的工业化制备
WO2013100878A1 (en)	2011-12-27	2013-07-04	Mahmut Bilgic	Pharmaceutical formulations comprising aripiprazole
WO2014104989A1 (en)	2011-12-27	2014-07-03	Mahmut Bilgic	Pharmaceutical compositions comprising aripiprazole
TW201343201A (zh)	2012-03-06	2013-11-01	Otsuka Pharma Co Ltd	持續釋放型口服固體製劑
WO2013142198A1 (en)	2012-03-19	2013-09-26	Alkermes Pharma Ireland Limited	Pharmaaceutical compositions comprising fatty acid esters
ES2764383T3 (es)	2012-03-19	2020-06-03	Alkermes Pharma Ireland Ltd	Composiciones farmacéuticas que comprenden ésteres de glicerol
CA2867137C (en)	2012-03-19	2020-12-08	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol
JOP20200109A1 (ar)	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	مستحضر قابل للحقن
KR101571670B1 (ko)	2012-08-08	2015-11-25	주식회사 씨엠지제약	아리피프라졸을 포함하는 경구용 속용 필름 제제
NZ631345A (en)	2012-09-19	2017-06-30	Alkermes Pharma Ireland Ltd	Pharmaceutical compositions having improved storage stability
WO2014059363A1 (en) *	2012-10-11	2014-04-17	Antrim Pharmaceuticals Llc	Oral solution formulations of aripiprazole
WO2014060324A1 (en)	2012-10-16	2014-04-24	Sanovel Ilac Sanayi Ve Ticaret A.S	Aripiprazole formulations
HK1215170A1 (zh)	2012-11-14	2016-08-19	The Johns Hopkins University	治療精神分裂症的方法和組合物
AR096131A1 (es)	2013-04-30	2015-12-09	Otsuka Pharma Co Ltd	Preparado oral sólido que comprende aripiprazol y un método para producir un preparado oral sólido que comprende aripiprazol
US10525057B2 (en)	2013-09-24	2020-01-07	Otsuka Pharmaceutical Co., Ltd.	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
WO2015067313A1 (en)	2013-11-07	2015-05-14	Synthon B.V.	Orodispersible pharmaceutical compositions comprising aripiprazole
CA2934553C (en)	2013-12-20	2023-10-31	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112016021535A8 (pt)	2014-03-20	2021-07-20	Alkermes Pharma Ireland Ltd	kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
KR20160139704A (ko)	2015-05-28	2016-12-07	주식회사 씨엠지제약	아리피프라졸을 포함하는 경구용 속용 필름 제제, 및 이의 제조방법
WO2016200830A1 (en)	2015-06-08	2016-12-15	Corium International, Inc.	Formulations for aripiprazole delivery transdermally
MA42624A (fr)	2015-06-19	2021-04-28	Agenebio Inc	Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
EP3310358A4 (en) *	2015-06-22	2019-08-28	Embera Neurotherapeutics, Inc.	COMPOSITIONS AND METHODS FOR TREATING SUBSTANCE ABUSE, SEARCH AND PSYCHIATRIC DISORDER
CN106608875A (zh)	2015-10-26	2017-05-03	江苏恩华药业股份有限公司	一种稠和杂环类衍生物合成及其应用
EP3490529A1 (en)	2016-07-28	2019-06-05	Mylan Laboratories Ltd.	Process for preparing sterile aripiprazole formulation
CN108069900B (zh) *	2016-11-08	2022-09-23	齐鲁制药有限公司	阿立哌唑盐酸盐的制备方法和用途
TR201617675A2 (tr)	2016-12-02	2018-06-21	Arven Ilac Sanayi Ve Ticaret Anonim Sirketi	Ari̇pi̇prazole monohi̇drat formülasyonlarinin ağizda dağilan tablet formu
US11505555B2 (en)	2016-12-19	2022-11-22	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en)	2016-12-19	2018-06-21	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019018700A2 (pt)	2017-03-10	2020-04-07	Embera Neurotherapeutics Inc	composições farmacêuticas e seus usos
CN111315722B (zh)	2017-07-28	2023-06-16	因特奎姆私人控股公司	制备月桂酰阿立哌唑的方法
CN109498556A (zh) *	2017-09-15	2019-03-22	万特制药(海南)有限公司	阿立哌唑口服溶液及其制备方法
CA3092335A1 (en)	2018-03-05	2019-09-12	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy
US11414425B2 (en)	2018-06-19	2022-08-16	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN109180577B (zh) *	2018-10-15	2021-11-16	迪嘉药业集团有限公司	一种阿立哌唑的制备方法
KR102128883B1 (ko)	2019-10-02	2020-07-01	(주)삼화바이오팜	고순도 아리피프라졸의 신규 결정형 및 이의 제조방법
WO2022212538A1 (en) *	2021-03-31	2022-10-06	Blueprint Medicines Corporation	Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
CN115611828A (zh) *	2021-07-15	2023-01-17	北京万全德众医药生物技术有限公司	一种阿立哌唑关键中间体ii的制备方法
TWI820847B (zh) *	2021-08-05	2023-11-01	大陸商上海樞境生物科技有限公司	含三并環類衍生物調節劑、其製備方法和應用
CN114751873B (zh) *	2022-04-25	2025-02-18	扬州市普林斯医药科技有限公司	一种1-(2,3-二氯苯基)哌嗪的制备方法
IL319072A (en)	2022-08-19	2025-04-01	Agenebio Inc	History of Benzazepine, Compositions and Methods for Treating Cognitive Impairment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3994900A (en) *	1976-01-23	1976-11-30	E. R. Squibb & Sons, Inc.	6-(Or 8)-[[(substituted amino)alkyl]oxy(or thio)]-3,4-dihydro-4-phenyl-2(1H)-quinolinones
JPS54130587A (en) *	1978-03-30	1979-10-09	Otsuka Pharmaceut Co Ltd	Carbostyryl derivative
DE2960178D1 (en) *	1978-06-06	1981-04-09	Hoechst Ag	New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
DE2827566A1 (de) *	1978-06-23	1980-01-10	Boehringer Mannheim Gmbh	1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung
PH17194A (en) *	1980-03-06	1984-06-19	Otsuka Pharma Co Ltd	Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS58203968A (ja) *	1982-05-21	1983-11-28	Otsuka Pharmaceut Co Ltd	イソカルボスチリル誘導体
DE3442570A1 (de) *	1984-11-22	1986-05-22	Hoechst Ag, 6230 Frankfurt	Neue substituierte phenylpiperazinderivate, verfahren zu deren herstellung und die verwendung substituierter phenylpiperazinderivate als aggressionshemmer fuer tiere
DK588486A (da) *	1985-12-09	1987-06-10	Otsuka Pharma Co Ltd	Anvendelse af en forbindelse til behandling af hypoxi

1989
- 1989-10-20 US US07/424,719 patent/US5006528A/en not_active Expired - Lifetime
- 1989-10-27 DE DE68925405T patent/DE68925405T2/de not_active Expired - Lifetime
- 1989-10-27 ES ES89120001T patent/ES2084594T3/es not_active Expired - Lifetime
- 1989-10-27 EP EP89120001A patent/EP0367141B1/en not_active Expired - Lifetime
- 1989-10-27 DE DE200412000043 patent/DE122004000043I2/de active Active
- 1989-10-30 DK DK539789A patent/DK168485B1/da not_active IP Right Cessation
- 1989-10-30 CN CN89108934A patent/CN1028104C/zh not_active Expired - Lifetime
- 1989-10-31 KR KR1019890015729A patent/KR0138529B1/ko not_active Expired - Lifetime
1992
- 1992-06-17 MX MX9202934A patent/MX9202934A/es unknown
1998
- 1998-02-27 HK HK98101538A patent/HK1002706A1/zh not_active IP Right Cessation
2004
- 2004-10-18 NL NL300161C patent/NL300161I2/nl unknown

Also Published As

Publication number	Publication date
DK539789D0 (da)	1989-10-30
DE122004000043I1 (de)	2005-02-03
DE68925405D1 (de)	1996-02-22
DK539789A (da)	1990-05-01
ES2084594T3 (es)	1996-05-16
EP0367141A2 (en)	1990-05-09
NL300161I2 (nl)	2005-02-01
NL300161I1 (nl)	2004-12-01
CN1042537A (zh)	1990-05-30
CN1028104C (zh)	1995-04-05
EP0367141A3 (en)	1991-06-12
US5006528A (en)	1991-04-09
KR900006320A (ko)	1990-05-07
HK1002706A1 (zh)	1998-09-11
DE68925405T2 (de)	1996-06-27
EP0367141B1 (en)	1996-01-10
KR0138529B1 (ko)	1998-05-15
DE122004000043I2 (de)	2005-06-16
MX9202934A (es)	1992-06-30

Publication	Publication Date	Title
DK168485B1 (da)	1994-04-05	Carbostyrilderivater, fremgangsmåde til fremstilling deraf og farmaceutisk præparat indeholdende et sådant carbostyrilderivat
EP0526434B1 (en)	2000-04-19	Benzimidazolone derivatives as 5-HT1A and 5-HT2 antagonists
KR960001722B1 (ko)	1996-02-03	카르보스티릴유도체 및 그것을 함유한 의약조성물
JPH02191256A (ja)	1990-07-27	カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
SK31793A3 (en)	1993-09-08	Pyridine and pyridine n-oxide derivatives of diaryl methyl piperidines and piperazines and compositions and methods of use thereof
DK166149B (da)	1993-03-15	Antipsykotiske 1-fluorphenylbutyl-4-(2-pyrimidinyl)-piperazinderivater, farmaceutiske praeparater indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne
HK1002706B (zh)	1998-09-11	2─羟喹啉衍生物
HU190997B (en)	1986-12-28	Process for preparing benzisothiazolyl-and benzisoxazolyl-piperazine derivatives
HUP0402576A2 (hu)	2005-05-30	5-HT antagonista tulajdonságú, gyógyászatilag hasznosítható kinolonvegyületek
WO2009022730A1 (ja)	2009-02-19	Ｐ２ｘ４受容体拮抗剤
CZ20021812A3 (cs)	2002-08-14	Nové cyklopropany jako antagonisté CGRP, farmaceutické prostředky obsahující tyto sloučeniny a způsob jejich výroby
NO860319L (no)	1986-07-31	Fremgangsmaate for fremstillig av terapeutisk aktive 4h-1-benzopyran-4-on-derivater og deres svovelholdige analoger.
CZ20014575A3 (cs)	2002-04-17	Nové deriváty piperazinylalkylthiopyrimidinu, farmaceutické kompozice je obsahující a způsob přípravy účinné látky
EP0567090B1 (en)	2000-07-26	Benzoxazepine derivatives as cholinesterase inhibitors
EP1585731A2 (en)	2005-10-19	Histamine h3 receptor antagonists, preparaton and therapeutic uses
RU2384572C2 (ru)	2010-03-20	Соли арипипразола
FI76794B (fi)	1988-08-31	Foerfarande foer framstaellning av nya terapeutiskt anvaendbara spirotiazolidindionderivat.
JPH0733744A (ja)	1995-02-03	インダゾール誘導体およびその塩
JPH0357903B2 (zh)	1991-09-03
JPH07304740A (ja)	1995-11-21	カルボスチリル誘導体
JPH0473435B2 (zh)	1992-11-20
JPH07165720A (ja)	1995-06-27	カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
JPS647990B2 (zh)	1989-02-10
KR101121662B1 (ko)	2012-03-09	도파민 ｄ3, ｄ4 수용체 길항제인 신규 3-(메톡시메틸)피라졸 유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물
JP3059572B2 (ja)	2000-07-04	ピロロ［３，２−ｅ］ピラゾロ［１，５−ａ］ピリミジン誘導体及びこれを有効成分とする高血圧治療剤

Legal Events

Date	Code	Title	Description
2005-01-03	CTFF	Application for supplementary protection certificate (spc) filed	Spc suppl protection certif: CA 2004 00035 Filing date: 20041201 Expiry date: 20141030
2006-10-09	CTFG	Supplementary protection certificate (spc) issued	Free format text: PRODUCT NAME: ARIPIPRAZOL, FOR PAEDIATRIC EXTENSION FILED: CA 2004 00035 EXT Spc suppl protection certif: CA 2004 00035 Filing date: 20041201
2009-11-16	PUP	Patent expired

Date

Code

Title

Description

2005-01-03

CTFF

Application for supplementary protection certificate (spc) filed

Spc suppl protection certif: CA 2004 00035

Filing date: 20041201

Expiry date: 20141030

2006-10-09

CTFG

Supplementary protection certificate (spc) issued

Free format text: PRODUCT NAME: ARIPIPRAZOL, FOR PAEDIATRIC EXTENSION FILED: CA 2004 00035 EXT